C012 | NOVEL ANALYSIS OF RESULTS FROM THE PIVOTAL EPCORE NHL-1 STUDY: OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AND COMPLETE RESPONSE AT 2-YEARS WITH EPCORITAMAB MONOTHERAPY

Background: Depth and duration of CR correlate with long-term outcomes in LBCL. Epcor is a subcutaneous CD3xCD20 bispecific antibody approved for the treatment (tx) of pts with DLBCL or high-grade BCL after ≥2 lines of tx (LOT). In the 3-y follow-up (FU) from NHL-1 (NCT03625037), epcor led to durab...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	P.L. Zinzani, Y. H. Karimi, J.M. Vose, M. Roost Clausen, D. Cunningham, U. Farooq, T. Feldman, H. Ghesquieres, W. Jurczak, K.M. Linton, T. Phillips, W.S. Kim, P. Jafarinasabian, M. Geybels, D. Soong, B. D. Månsson, C. W. Eskelund, M. Atiya, M. Hutchings, C. Thieblemont, C.Y. Cheah
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Ferrata Storti Foundation 2025-09-01
Σειρά:	Haematologica
Διαθέσιμο Online:	https://haematologica.org/article/view/12876
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!